UY36006A - Construcciones de proteína uspa2 y usos de las mismas. - Google Patents

Construcciones de proteína uspa2 y usos de las mismas.

Info

Publication number
UY36006A
UY36006A UY0001036006A UY36006A UY36006A UY 36006 A UY36006 A UY 36006A UY 0001036006 A UY0001036006 A UY 0001036006A UY 36006 A UY36006 A UY 36006A UY 36006 A UY36006 A UY 36006A
Authority
UY
Uruguay
Prior art keywords
uspa2
same
compositions
immunogenic compositions
uspa2 protein
Prior art date
Application number
UY0001036006A
Other languages
English (en)
Spanish (es)
Inventor
Castado Cindy
Chomez Patrick
Dewerchin Marianne
Blais Normand
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of UY36006A publication Critical patent/UY36006A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/102Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/104Pseudomonadales, e.g. Pseudomonas
    • A61K39/1045Moraxella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C07K14/212Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1218Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Acinetobacter
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55577Saponins; Quil A; QS21; ISCOMS
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
UY0001036006A 2014-02-24 2015-02-20 Construcciones de proteína uspa2 y usos de las mismas. UY36006A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461943909P 2014-02-24 2014-02-24
US201461946937P 2014-03-03 2014-03-03
US201461946932P 2014-03-03 2014-03-03

Publications (1)

Publication Number Publication Date
UY36006A true UY36006A (es) 2015-09-30

Family

ID=52629643

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036006A UY36006A (es) 2014-02-24 2015-02-20 Construcciones de proteína uspa2 y usos de las mismas.

Country Status (28)

Country Link
US (3) US10040832B2 (enExample)
EP (2) EP3498292B1 (enExample)
JP (1) JP6585085B2 (enExample)
KR (1) KR102515835B1 (enExample)
CN (2) CN106061995A (enExample)
AU (1) AU2015220369B2 (enExample)
BE (1) BE1022345A9 (enExample)
BR (1) BR112016019525B1 (enExample)
CA (1) CA2939862C (enExample)
CY (2) CY1121535T1 (enExample)
DK (2) DK3110438T3 (enExample)
EA (1) EA034352B1 (enExample)
ES (2) ES2715674T3 (enExample)
HR (2) HRP20211926T1 (enExample)
HU (2) HUE057505T2 (enExample)
IL (1) IL246994B (enExample)
LT (2) LT3498292T (enExample)
ME (1) ME03335B (enExample)
MX (1) MX376079B (enExample)
PL (2) PL3498292T3 (enExample)
PT (2) PT3110438T (enExample)
RS (2) RS58451B1 (enExample)
SG (1) SG11201606272PA (enExample)
SI (2) SI3498292T1 (enExample)
SM (2) SMT201900166T1 (enExample)
TW (1) TW201620927A (enExample)
UY (1) UY36006A (enExample)
WO (1) WO2015125118A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201620927A (zh) * 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Uspa2蛋白質構築體及其用途
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
JP2020515587A (ja) * 2017-03-31 2020-05-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited 免疫原性組成物、使用及び処置方法
FR3066920A1 (fr) 2017-05-30 2018-12-07 Glaxosmithkline Biologicals S.A. Nouveaux procedes de fabrication d'un adjuvant
MX2020001820A (es) * 2017-08-14 2020-03-20 Glaxosmithkline Biologicals Sa Metodos para reforzar las respuestas inmunitarias.
CN111670044A (zh) 2017-12-01 2020-09-15 葛兰素史密丝克莱恩生物有限公司 皂苷纯化
GB201803692D0 (en) * 2018-03-08 2018-04-25 Glaxosmithkline Biologicals Sa Immunogenic composition
CA3107077A1 (en) 2018-08-07 2020-02-13 Glaxosmithkline Biologicals Sa Processes and vaccines
US20210220462A1 (en) * 2018-08-23 2021-07-22 Glaxosmithkline Biologicals Sa Immunogenic proteins and compositions
WO2020109365A1 (en) 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
WO2020212461A1 (en) 2019-04-18 2020-10-22 Glaxosmithkline Biologicals Sa Antigen binding proteins and assays
JP7640473B2 (ja) 2019-06-05 2025-03-05 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
JP2022543264A (ja) * 2019-08-05 2022-10-11 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム プロテインdポリペプチドを含む組成物を調製するプロセス
CA3148924A1 (en) 2019-08-05 2021-02-11 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2021048159A1 (en) 2019-09-11 2021-03-18 Glaxosmithkline Biologicals Sa Assay
JP2024510717A (ja) 2021-02-22 2024-03-11 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物、使用及び方法
EP4558170A1 (en) 2022-07-19 2025-05-28 GlaxoSmithKline Biologicals S.A. Continuous process for vaccine production

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
DE69327599T2 (de) 1992-06-25 2000-08-10 Smithkline Beecham Biolog Adjuvantien enthaltende Impfstoffzusammensetzung
WO1994021292A1 (en) 1993-03-23 1994-09-29 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP1167378B1 (en) 1994-07-15 2011-05-11 University of Iowa Research Foundation Immunomodulatory oligonucleotides
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE69740108D1 (de) * 1996-12-20 2011-03-10 Univ Texas Moraxella catarrhalis antigene uspa1 und uspa2
ES2298269T3 (es) 2000-09-26 2008-05-16 Idera Pharmaceuticals, Inc. Modulacion de la actividad inmunoestimulante de analogos oligonucleotidicos inmunoestimulantes mediante cambios quimicos posicionales.
AU2002258734A1 (en) * 2001-04-13 2002-10-28 Wyeth Holdings Corporation Removal of bacterial endotoxin in a protein solution by immobilized metal affinity chromatography
CA2452836C (en) * 2001-07-27 2012-11-27 Chiron Srl Meningococcus adhesins nada, app and orf 40
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
JP5269594B2 (ja) * 2005-08-10 2013-08-21 アルネ・フオシユグレン・アー・ベー モラクセラ・カタラーリスと上皮細胞、細胞外マトリックス蛋白質及び補体系の相互作用
ZA200800891B (en) * 2005-08-10 2009-06-24 Arne Forsgren Ab Interaction of moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system
SG175492A1 (en) * 2006-01-17 2011-11-28 Arne Forsgren A novel surface exposed haemophilus influenzae protein (protein e; pe)
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
KR20140066126A (ko) * 2011-05-11 2014-05-30 리스벡 헬스케어 스웨덴 에이비 단백질 f - 라미닌 및 비트로넥틴 결합 특성을 갖는 신규한 헤모필러스 인플루엔자 부착분자
TW201620927A (zh) * 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Uspa2蛋白質構築體及其用途

Also Published As

Publication number Publication date
HRP20190412T1 (hr) 2019-04-19
EA201691611A1 (ru) 2016-12-30
US20170008932A1 (en) 2017-01-12
BR112016019525B1 (pt) 2024-01-02
SG11201606272PA (en) 2016-09-29
KR20160124774A (ko) 2016-10-28
EP3498292A1 (en) 2019-06-19
IL246994B (en) 2020-11-30
CN111499701A (zh) 2020-08-07
BE1022345A9 (fr) 2016-11-16
MX2016010954A (es) 2016-11-11
US10947280B2 (en) 2021-03-16
PL3498292T3 (pl) 2022-02-14
TW201620927A (zh) 2016-06-16
EP3110438B1 (en) 2019-01-02
AU2015220369A1 (en) 2016-09-15
DK3110438T3 (en) 2019-03-25
CA2939862A1 (en) 2015-08-27
ME03335B (me) 2019-10-20
WO2015125118A1 (en) 2015-08-27
PT3110438T (pt) 2019-03-29
EA034352B1 (ru) 2020-01-30
PL3110438T3 (pl) 2019-06-28
US10040832B2 (en) 2018-08-07
PT3498292T (pt) 2021-11-18
LT3498292T (lt) 2021-11-25
MX376079B (es) 2025-03-07
HRP20211926T1 (hr) 2022-03-18
JP6585085B2 (ja) 2019-10-02
SI3110438T1 (sl) 2019-05-31
BR112016019525A2 (pt) 2017-10-24
CN106061995A (zh) 2016-10-26
ES2899300T3 (es) 2022-03-10
HUE057505T2 (hu) 2022-05-28
US20180354996A1 (en) 2018-12-13
US20200325184A1 (en) 2020-10-15
JP2017507181A (ja) 2017-03-16
CY1121535T1 (el) 2020-05-29
DK3498292T3 (da) 2022-01-03
RS58451B1 (sr) 2019-04-30
EP3498292B1 (en) 2021-10-20
EP3110438A1 (en) 2017-01-04
RS62592B1 (sr) 2021-12-31
IL246994A0 (en) 2016-09-29
CY1124979T1 (el) 2022-11-25
BE1022345B1 (fr) 2016-03-25
US10745449B2 (en) 2020-08-18
ES2715674T3 (es) 2019-06-05
CA2939862C (en) 2022-12-06
SMT201900166T1 (it) 2019-05-10
SI3498292T1 (sl) 2022-01-31
KR102515835B1 (ko) 2023-03-31
HUE042054T2 (hu) 2019-06-28
SMT202100728T1 (it) 2022-01-10
LT3110438T (lt) 2019-04-10
AU2015220369B2 (en) 2018-02-01

Similar Documents

Publication Publication Date Title
UY36006A (es) Construcciones de proteína uspa2 y usos de las mismas.
NI201800052A (es) Anticuerpos que neutraliza el virus respiratorio sincitial humano
DOP2013000235A (es) Proteínas de fusión y vacunas de combinación que comprenden proteína e y pilina a de haemophilus influenzae.
MX387985B (es) Particulas tipo virus modificadas de cmv.
MX2015008847A (es) Composiciones inmunogenicas de virus de influenza y usos de las mismas.
BR112018012873A2 (pt) vacina de vírus zika
WO2014113490A3 (en) Immunogenic wt-1 peptides and methods of use thereof
WO2013106834A3 (en) Immunogenic wt-1 peptides and methods of use thereof
PT3096785T (pt) Composições imunogénicas que compreendem antigénios de sacáridos capsulares conjugados e utilizações das mesmas
EA201691348A1 (ru) Однофлаконные вакцинные составы
MX2015010783A (es) Composicion de vacuna.
AR102547A1 (es) Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
PH12015000376A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
DK3146042T3 (da) Rekombinant klassisk svinepestvirus (CSFV) med substitution i E2-proteinets TAV-epitop
MX363149B (es) Vacunas de nucleoproteina de la influenza.
BR112014020025A8 (pt) Vacinas de subunidade de rotavirus e métodos de produção e uso das mesmas
MX2016010838A (es) Vacunas de proproteina convertasa subtilisina/kexina tipo 9 (pcsk9).
EA201792512A1 (ru) Составы для доставки антигенов респираторного синтициального вируса и норовируса в тонкий кишечник
MX381745B (es) Vacunas de pestivirus para temblores congenitos.
CL2019000705A1 (es) Nuevos promotores.
EP3538197A4 (en) DEVICES AND METHODS FOR IMPROVING IMMUNOGENICITY TO INTRADERMAL VACCINATION
WO2015070207A3 (en) Ama-1 epitopes, antibodies, compositions, and methods of making and using the same
WO2014121037A8 (en) Hydroxylamine-terminated polysiloxane and methods of making and using the same
AR099553A1 (es) Construcciones de proteína uspa2 y usos de las mismas

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20220610